Philippe Moreau MD; IMS 2026: International Myeloma Society President Discusses Key Themes, Future Directions and Challenges in Newly Diagnosed Multiple Myeloma
GLASGOW, Scotland—Philippe Moreau MD, President of the International Myeloma Society, talks with Audio Journal of Oncology correspondent Sarah Maxwell about the key themes, future directions and challenges in newly diagnosed multiple myeloma under discussion at the 2026 Annual Meeting, including new drugs and the prospects for cure.
International Myeloma Society President Discusses Key Themes, Future Directions and Challenges in Newly Diagnosed Multiple Myeloma.
An interview with:
Philippe Moreau MD, President of the International Myeloma Society, Professor of Clinical Hematology, head of the Translational Research Program for Hematology and Oncology,University Hospital Hôtel-Dieu, Nantes, France.
GLASGOW, Scotland—Philippe Moreau MD, President of the International Myeloma Society, talks with Audio Journal of Oncology correspondent Sarah Maxwell about the key themes, future directions and challenges in newly diagnosed multiple myeloma under discussion at the 2026 Annual Meeting, including new drugs and the prospects for cure.
AUDIO JOURNAL OF ONCOLOGY; Philippe Moreau MD:
IN: Hello and Welcome ….
OUT:….from me, Sarah Maxwell, Bye Bye for now. 9:52 secs
International Myeloma Society 2026 Annual Meeting Program:
#Interview #PhilippeMoreauMD #PhilippeMoreau #Hematology #Oncology #Cancer #MultipleMyeloma #NewlyDiagnosedMultipleMyeloma #InternationalMyelomaSociety #IMS2026 #IMSGlasgow #InternationalMyelomaSociety2026
#InternationalMyelomaSocietyAnnualMeeting #23rdInternationalMyelomaSocietyMeeting #AudioJournalOfOncology
References
Related Episodes
Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse
GLASGOW, Scotland—Joseph Mikhael MD, Professor at the Translational Genomics Research Institute (TGen), Phoenix, Arizona USA, talks with Sarah Maxwell at the International Myeloma Society 2026 Annual Meeting about the importance of introducing B-cell maturation antigen-targeted therapies at first relapse for patients with multiple myeloma.